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ABSTRACT 
Celiac Disease (CD) is a chronic inflammatory and autoimmune disorder of 
the small intestine characterized by an aberrant immune response to gluten proteins 
(primarily gliadins). Gluten are found in wheat, barley and rye and cause CD in 
genetically predisposed individuals. The genetic predisposition is given by the 
presence of either HLA-DQ2 or HLA-DQ8 genes in CD patients. Autoantibodies to 
tissue transglutaminase (TG2) and gluten are present as a consequence of the 
activation of the adaptive immune system. CD presents clinically with diarrhea and 
intestinal discomfort due to villous atrophy and may lead to anemia, osteoporosis 
and lymphomas. 
All signs and symptoms of celiac disease are triggered by the ingestion of 
gluten. Thus, the treatment of CD consists of strict exclusion of gluten from the diet, 
being the only treatment option currently available. The diet is very difficult to comply 
with, and gluten contamination in foods is a major problem for the CD patient 
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population. There is a clear need for a non-dietary approach that could alleviate the 
fear of accidental gluten ingestion. 
The human proteolytic enzymes pepsin, trypsin and chymotrypsin are unable 
to fully degrade gluten proteins. Gluten proteins are rich in praline and glutamine 
residues, which are enriched in immunogenic domains. A33-mer, a-gliadin-derived, 
highly immunogenic peptide has been identified, which is highly resistant to 
degradation by the mammalian digestive enzymes 
Evidence obtained in our laboratory has shown that gluten-degrading 
enzymes are produced by bacteria that naturally colonize the oral cavity. The more 
downstream region of the human gastrointestinal tract harbors even more microbes 
than the oral cavity. Therefore, the aim of the present study was to investigate if 
gluten-degrading bacteria can be harvested from human feces. 
Aliquots of human fecal samples were collected under aseptic conditions from 
3 healthy human subjects and suspended in 1 ml phosphate buffered saline (PBS). 
A 10-fold serial dilution was prepared and 50 µI aliquots were plated on gluten agar 
plates at pH 4.0 and 7.0, and incubated aerobically or anaerobically. Strains were 
subcultured to purity on Bruce/la agar plates. Gluten degradation by the bacterial 
strains was assessed in gliadin zymograms which were developed at pH 4.0 or pH 
7.0. Furthermore, we assessed the cleavage of synthetic tripeptide substrates 
derived from gliadin, determined gliadin degradation in solution by SOS-PAGE and 
studied the degradation of the 33-mer peptide by RP-HPLC. 
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Using the selective plating approach, 278 fecal strains were isolated. All 
strains were subjected to gliadin degradation in zymography, yielding 43 active 
strains. Of these, 40 strains hydrolyzed one or more of the trpeptide substrates. The 
substrate LPY was most frequently and the most rapidly hydrolyzed. Three of the 
strains (FA-14, FA-16 and FA-25) were able to cleave one or two of the tripeptides 
also at acidic pH (4.0). Of the 40 strains, 22 were selected for studying 33-mer 
degradation, obtaining 16 active strains. 
Using the selective plating approach, gluten-degrading microorganisms were 
successfully isolated from feces. These bacteria or their enzymes may be useful for 
the future development of new treatment modalities for CD. 
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1. INTRODUCTION 
1.1 Wheat 
Wheat is a grain type widely used in the manufacturing of food. It is easily 
cultivable in many climates and soil types and it can be stored for long periods of 
time due to its low content of water. Over 600 million tons of wheat are harvested 
annually. Its popularity is due to its adaptability to any kind of weather and specially 
the unique characteristics that it confers to the dough (e.g. viscoelasticity). The 
dough can be processed as biscuits, pasta, noodles, different kinds of breads, 
cakes, etc. Gluten is the term used to describe the mixture of storage proteins 
(prolamins) (Shewry, 2009). Wheat proteins are composed of albumins, which are 
the smallest of the wheat proteins and soluble in water, globulins which are larger 
than albumins and soluble in dilute NaCl solution, and prolamins, comprising gliadins 
and glutenins which are very complex proteins and insoluble in water. Gliadins are 
soluble in 70% ethyl alcohol and glutenins are soluble in dilute acid or sodium 
hydroxide solutions. The latter are responsible for the sticky consistency of dough 
(Mann et al., 2013). Prolamins (gluten) are characterized by a particular amino acid 
composition and domains with an unusually high content of proline and glutamine. It 
is known that certain gluten and gliadin derived domains are resistant to degradation 
by ga~tric and pancreatic proteases in the human gastrointestinal tract, resulting in 
the accumulation of relatively large peptide fragments (Shan et al., 2002, 2005). 
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Figure 1. Wheat composition. Gliadins and glutenins, together called gluten, are the 
storage proteins of wheat. Peptides highly resistant to proteolysis by the human 
proteolytic enzymes are responsible for the development of Celiac Disease in 
genetically predisposed individuals. 
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1.2 Human digestive system 
The human digestive system comprises all the organs, enzymes and secretions 
involved in the intake, degustation, breakdown, absorption and elimination of 
ingested foods. The digestive tract is composed of the mouth, esophagus, stomach, 
pancreas, liver and the small and large intestines (Patton and Thibodeau, 2000). 
Digestion starts in the oral cavity with the mastication of foods and mixing with 
saliva. There, the breakdown of polysaccharides by the salivary enzyme amylase is 
initiated, as well as the breakdown of fats by the enzyme lipase. Besides providing 
enzymes, saliva also facilitates swallowing, maintains mouth moisture, dissolves 
molecules that stimulate taste, helps maintain teeth clean and provides a mildly 
alkaline rinse for the esophagus. The food being chewed is mixed together with 
saliva forming the food bolus which is swallowed and delivered to the stomach. 
Once in the stomach the bolus is mixed with HCI, mucus and the digestive enzyme 
pepsin. Only part of the enzymatic/chemical digestion of foods actually occurs in the 
stomach. The mixture of the bolus with stomach acids is now called chyme and 
enters the duodenum which is the first segment of the small intestine, followed by 
the jejunum and ileum. In the duodenum the chyme is mixed with mucosal cell 
secretions, exocrine pancreatic juice and bile. Mucus is secreted by Brunner glands 
in the duodenum and by goblet cells in the mucosa throughout the intestines. The 
function of mucus secretion along the gastrointestinal tract is to provide lubrication, 
bind bacteria _ and trap immunoglobulins to increase their access to pathogens. 
Intestinal secretions are generally alkaline to neutralize the acidic nature of the 
chyme entering from the stomach. Most of the digestion, breakdown of foods and 
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absorption of nutrients occurs in the small intestine. The next step is for the 
undigested matter to enter the large intestine which functions are mainly the 
reabsorption of fluid and electrolytes. Also in the large intestine, bacterial digestion 
of some complex carbohydrates takes place. The bacteria colonizing the large 
intestine are considered normal flora of that anatomic site and have numerous 
functions, important for the host. They synthesize vitamin K, B complex vitamins and 
folic acid, split urea to NH3 and produce small organic acids from unabsorbed fat 
and carbohydrates. Normal feces will still contain undigested plant fibers. Excreted 
bacteria account for approximately 30% of the fecal solids. Inorganic matter, water 
and non-dietary waste material as bile and bilirubin are also present in the fecal 
matter. The brown color of the feces is given by the action of bacteria on bile 
pigments (Patton and Thibodeau, 2000). 
1.3 Digestion and absorption 
Carbohydrates, fats and proteins are broken down by different enzymes and are 
reabsorbed at different and specific sites in the small intestines. 
When a protein enters the stomach, it is cleaved and converted by the enzyme 
pepsin and stomach's HCI into peptides. About, 10-15% of protein is broken down 
completely into amino acids in the stomach. Pepsin functions best at pH 1.5 and is 
irreversibly deactivated above pH 5.0 (Patton and Thibodeau, 2000). Therefore, 
gastric secretion of HCI is indispensable. When the peptides reach the duodenum 
the enzymes trypsin and chymotrypsin continue breaking down the peptides into 
smaller peptides or single amino acids. Approximately, 50% of protein is completely 
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digested and absorbed by the time it reaches the duodenum and jejunal intersection. 
The rest of the peptides are typically absorbed by the villi in the jejunum of the small 
intestine (Patton and Thibodeau, 2000). Complex proteins like glutenins and gliadins 
from wheat however are, to some extent, resistant to proteolysis. Unlike other 
proteins they contain domains that are not completely broken down into small 
peptides or single amino acids. Some gliadin peptides enter the duodenum as 
relatively large fragments that cannot be readily absorbed. 
1.4 Celiac Disease 
1.4.1 CD Incidence and Onset 
Celiac disease (CD) is a chronic inflammatory disease of the small intestine that 
is triggered and maintained by the storage proteins (gluten) of wheat, barley and rye 
in genetically predisposed individuals who carry the genes HLA-DQ2 or HLA-DQB 
(Schuppan et al., 2009). CD has a prevalence of 0.5 - 2.0% in populations of 
European ancestry (Sanz et al., 2011 ). The disease can manifest at any age. It 
usually appears early in life after the introduction of wheat into the diet, but in most 
cases CD is diagnosed only in adulthood. There seems to be a correlation between 
early exposure to gluten and development of the disease. A study showed that 
infants genetically predisposed for CD may benefit from delaying the exposure to 
gluten to at least 1 year of age (Sellitto et al., 2012). Frequent rotavirus infections 
have also been suggested to be a risk factor for CD in early childhood because this 
virus causes a transient increased in the intestinal permeability and also an 
5 
upregulation and release of tissue transglutaminase. These two actions facilitate the 
deamidation of cereal peptides and a rapid inflammatory response in genetically 
predisposed children (Stene et al., 2006). The duration of breast-feeding and the 
introduction of gluten while the infant is still being breast-fed has demonstrated to 
reduce the risk of developing CD, evidenced by a study on the Swedish epidemic of 
CD (lvarsson, 2005). 
1.4.2 Non-CD Gluten Sensitivities 
There are two other wheat-triggered diseases that are occasionally 
misdiagnosed as CD. The first is wheat allergy (WA) which is a type 1 anaphylactic 
reaction where there is a crosslink between gluten and lgE that triggers the release 
of histamine from basophils and mast cell, as well as other chemical mediators. 
Clinically it is present in a variety of forms including, skin, gastrointestinal tract or 
respiratory tract reactions, baker's asthma, rhinitis and contact urticaria. It is different 
from CD in that the serology for the autoantibodies to TG2 is negative and no 
intestinal histological changes are present. It is similar in that oral consumption of 
wheat is the triggering agent. The second is gluten sensitivity (GS) where patients 
do not tolerate gluten and have similar gastrointestinal symptoms as those seen in 
CD, but do not have damage in the small intestine and TG2 auto-antibodies are not 
present. The diagnosis of GS is made by exclusion of patients in either the CD or 
wheat allergy category and by obtaining improvement of the symptoms upon gluten 
elimination from the diet (Sapone et al., 2012). 
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1.4.3 CD Diagnostic Parameters 
At the serological level, most CD patients that are not on a gluten-free diet 
and are positive for the circulating autoantibodies to the tissue transglutaminase 
(TG2) (Meresse et al., 2012). In addition, genetically, all CD patients harbor the 
genes HLA-DQ2 or HLA-DQ8 (Schuppan et al., 2009). Clinically, CD can be 
symptomatic, silent or asymptomatic . The symptomatic presentation is characterized 
by individuals with positive serology for TG2 autoantibodies and duodenal tissue 
lesion including flattening of the villi, crypt hyperplasia and intraepithelial 
lymphocytosis, confirmed by a biopsy. These histological lesions lead to the classic 
clinical manifestations of CD which are weight loss, chronic diarrhea, abdominal 
distention and impaired growth due to malabsorption . Silent CD includes individuals 
whose serology and biopsy are positive for CD but no symptoms are reported, 
representing a risk for autoimmune and malignant complications. Asymptomatic CD 
refers to individuals with positive serology but normal intestinal mucosa and no 
symptoms. This is also called latent or potential CD, because some eventually 
develop the disease (Meresse et al., 2012). According to Schuppan and coworkers 
in (2009), there is another presentation of CD known as atypical, characterized by 
arthritis, infertility, hypertransaminasemia and liver failure. 
1.4.4 Genetic Predisposition to CD 
The genes HLA-DQ2 and HLA-DQ8 have positively charged pockets on their 
surface, which makes them bind to negatively charged molecules. The gluten 
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peptides rich in proline (P) and glutamine (Q) residues are excellent substrates for 
the enzyme TG2. This enzyme converts certain neutral glutamine residues in 
gluten/gliadin proteins into negatively charge glutamic acid residues increasing their 
affinity for HLA-DQ2/8. Consequently, the HLA-DQ2/8+ dendritic cells can activate 
gluten-specific CD4+ T cells in the lamina propria. These cells stimulate B cells 
which produce antibodies to gluten or TG2 (lgA), constituting the adaptive or B cell-
mediated immune response in CD patients (Meresse et al., 2012). CD4+ T cells are 
central effectors of the intestinal inflammation via the production of INF-y (Schuppan 
et al., 2009). However, Meresse et al. in 2012 postulated that the cause of the small 
intestinal tissue damage is the chronic activation of intestinal intraepithelial 
lymphocytes (IELs), specifically the subset CD8+-T-cell population. It is not clear 
what induces the activation of these cells. One theory is that a direct recognition by 
the IELs of some gluten peptides leads to the subsequent production of INF-y. 
Another theory is that both IL-21 produced by the CD4+ T cells and IL-15 produced 
by the enterocytes, cause the activation and expansion of CD8+ T I Els in CD. The 
mechanisms involved in the over expression of IL-15 in CD patients remains 
unclear. In order to link the CD8+ and the CD4+ T cell responses it is hypothesized 
that CD4+ T cells are necessary to induce dendritic cells for CD8+ T stimulation. 
And IL-15 may then be in charge of the survival of activated CD8+ T cells (Meresse 
et al., 2012). The postulated pathways for the activation of the immune system in CD 
are outlined in Figure 2. 
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Figure 2. Pathogenesis of Celiac Disease (Simplified scheme). The Gluten 
peptides resistant to proteolysis reach the lamina propria by a mechanism not yet 
elucidated, and are deamidated by the enzyme TG2. The deamidated peptides are 
then presented to the CD4+ T cells by the antigen-presenting cells in the HLA-DQ2 
or HLA-DQB context. The activated CD4+ T cells produce Th1 cytokines such as 
INF-a, resulting in mucosal tissue remodeling and villous atrophy through the 
release and activation of MMPs. Moreover CD4+ T cells activate B cells that 
produce autoantibodies to gluten and TG2 (lgA). Production of IL-21 by CD4+ T 
cells, in concert with IL-15 produced in by enterocytes and antigen presenting cells 
sensitized by the gluten epitopes, activate CDB+-T IELs, causing and maintaining 
damage in the intestinal tissue. Picture adapted from: Schuppan et al., 2009. 
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1.4.5 CD lmmunogenic Gluten Epitopes 
The gluten immunogenic epitopes have been identified. One a-gliadin domain 
that is of special concern is a 33-mer peptide (Shan et al., 2002). The a-gliadin 33-
mer peptide is entirely resistant to digestion by mammalian digestive enzymes. 
Furthermore, it is highly reactive to isolated celiac T cells due to the presence of 
multiple immunogenic epitopes in its sequence (Koning et al., 2005). Therefore, it is 
one of the main immunogenic toxic gliadin peptides in CD. It is a relatively large 
fragment with the sequence LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF, 
. ' 
spanning residues 57 to 89 in a-gliadin. Another highly immunogenic peptide is any-
gliadin-derived 26-mer peptide FLQPQQPFPQQPQQPYPQQPQQPFPQ which, like 
the 33-mer peptide is also highly resistant to proteolysis (Comino et al. 2012). 
1.4.6 Treatment strategies for CD 
Elimination of gluten from the diet is the only treatment available so far for CD 
patients. Wheat is present in many food products, making the adherence to a gluten-
free diet (GFD) a challenge. It usually reverses the symptoms except for patients 
with Refractory Celiac Disease, who need treatment with corticosteroids and other 
immunosuppressants to manage the inflammation in the duodenum (Schuppan et 
al., 2009). 
Several therapeutic options are being studied to treat CD, as alternative or 
adjunctive treatments to a GFD. There are three categories of these therapies 
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depending on what the focus of action is. The subdivisions are intraluminal, epithelial 
or sub-epithelial. These novel promising approaches, just to mention a few, are 
genetic modification of wheat to generate species with lower contents of 
immunogenic gluten moieties, pretreatment of flours with microbial transglutaminase 
to cross-link glutamine residues, oral enzyme therapy to aid in the digestion of 
gluten, neutralizing gluten antibodies, gluten binders, tissue transglutaminase 
inhibitors, and immune modulation to restore tolerance to gluten (Schuppan et al., 
2009). 
Oral enzyme therapy, which is the focus of this study, uses non-human enzymes .. 
to degrade the gluten peptides, if not completely, at least to an extent that 
they are not able to elicit anymore an immune response. Some of these 
enzymes are derived from microorganisms. 
1.5 The Human Microbiome 
The human microbiome is the collection of microorganisms including bacteria, 
fungi and archaea that reside on and within the adult human body. The numbers of 
bacteria associated with the human body are estimated to greatly exceed the 
number of eukaryotic cells that compose the human body (Camp et al.,2009). 
Microbial cells contribute to human's health and disease. The collective genome of 
the human microbiome encodes for physiologic capabilities that are not present in 
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the human's genome (Camp et al. , 2009). Thus, the host and its microbiome 
combined can be considered as one functional organism. 
The microorganisms expected to be present under normal healthy conditions 
are known as the normal flora. The normal flora helps to maintain natural processes 
necessary for a healthy body in different organs and systems . The human digestive 
enzymes are incapable to digest the variety of foods that are part of the normal diet. 
Indeed, microbial enzymes are needed to degrade certain types of food, and thus 
can be viewed as indispensable (Brown et al., 2012). A good example is that 
bacteria belonging to the bacteroides genus, which are healthy inhabitants of the 
human gut, break down otherwise non-digestible polysaccharides into simpler 
molecules such as small chain fatty acids (SCFAs), that can be further metabolized 
by the host (Turnbaugh et al., 2006) 
1.6 The Oral Microbime 
The oral cavity constitutes the most proximal part of the gastro intestinal tract. It 
is the main gate to everything a human consumes . While the oral cavity shows a rich 
microbial colonization, the most populated compartment of the gastrointestinal tract 
is the colon. 
A study analyzed 120 saliva samples from healthy individuals of 12 different 
countries and showed that there is some variation of the oral microbiome between 
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and within subjects but overall it does not vary substantially between people at 
different geographic sites (Nasidze et al., 2009). 
There are over 600 bacterial taxa in the oral cavity, distributed over different 
habitats including the teeth, gingival sulcus, tongue, cheeks, hard and soft palates 
and tonsils (Dewhirst et al., 2010). The over 600 taxa belong to 13 phyla. The 6 
major phyla being Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, 
Proteobacteria and Spirochetes containing 96% of the taxa. The remaining phyla are 
Chlamydiae, Chloroflexi, Euryarchaeota, SR1, Synergistetes, Tenericutes and TM?, 
together containing the residual 4% of the taxa (Chen et al., 2010). The oral bacteria 
live attached to the different tissues present in the mouth. They create local disease 
when the equilibrium between bacterial growth and host defense mechanisms is 
disturbed. Examples of oral disease are tooth caries, periodontitis and alveolar 
osteitis. Studies are now also linking the oral microbiome with a number of systemic 
diseases including diabetes, pneumonia, cardiovascular disease and stroke 
(Rathnayake et al., 2013). 
The microbial community of the oral cavity can also be viewed as a rich source of 
microorganisms with different capacities that contribute to the human body's 
functions. Our recent studies have presented evidence that common oral microbial 
species are able to cleave gluten peptides, including the "superantigen" 33-mer 
peptide. They were found when studying the salivary praline-rich proteins and 
realizing that these proteins are similar to gluten proteins. Dental plaque samples 
were assessed for their gluten degrading capacities in different assays. The 
investigation resulted in the identification and characterization of oral gluten-
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degrading microorganisms (Helmerhorst et al., 2010; Zamakhchari et al., 2011). 
Continuous investigations are being carried out in order to isolate the gluten-
degrading enzymes from these specific bacteria to be potentially used as oral 
enzyme therapy for CD patients. 
1.7 The Gut Microbiome 
The gastrointestinal tract contains the majority of microorganisms that inhabit the 
human body. There, they contribute to the host's health and pathology and live in 
balance with the surrounding tissues (Camp et al., 2009). The immune system 
keeps the gut microbiota controlled and prevents infections, unless the balance is 
disturbed. In a healthy human adult 10 bacterial phyla have been identified. They are 
Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria, 
Verrucomicrobia. Cyanobacteria, TM?, Spirchaetes and VadinBE97. There is a large 
diversity of strains in the different phyla (Stearns et al., 2011 ). 
A study of the human gut microbiome viewed across age and geography 
revealed that differences in social structures may influence the extent of microbial 
transmission between members of a household. Cultural differences like food, 
exposure to pets and livestock might influence from where the gut microbiota is 
acquired (Yatsunenko et al., 2012). Another study demonstrated that an alteration of 
the host habitat or life style (i.e. sickness or diet) directly impacts the gut microbial 
community which as a consequence alters the host's physiology. Some of the 
diseases that show altered gut microbial colonization are inflammatory bowel 
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disease, obesity and CD as reviewed by several investigators (Kinross et al.; Sartor, 
Sokol et al.; DiBaise et al.). In the case of CD, a study comparing the gut 
microbiome of CD patients and healthy controls showed a reduction in the level of 
harmless organisms such as lactobacilli and bifidobacteria and an increase of 
potentially harmful organisms belonging to the Prevotella genus, and E. coli (De 
Palma et al., 2009). In another study it was observed that the species variation of 
gut microflora in celiac patients is less than the inter-individual variation observed in 
healthy controls, suggesting a stable and different microbial community in celiac 
patients (Schippa et al., 2010). While the above observations clearly seem to point in 
the direction that the gut microbiomes differ between health and disease, it remains 
to be determined whether this alteration is the cause or the consequence of the 
disease. 
Based on the findings that gluten-degrading bacteria are natural colonizers of 
the human oral cavity and knowing that the genes encoded by the bacteria present 
in the gut complement the human genome in functions pertinent to the digestion of 
certain food molecules, we hypothesize that gut microbes may also play a role in the 
digestion of gluten proteins. Therefore, in this present study we focus on the 
isolation of gluten-degrading bacteria from human feces. 
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2. AIM OF THE STUDY 
The specifics Aims of this investigation are to: 
1. Collect human fecal samples from three healthy donors. 
2. Culture bacteria using selective agar plates with gluten as the unique 
substrate. 
3. Assess the gluten-degrading capacity of the isolated microorganisms by 
testing gliadin degradation in gel and in solution, by measuring the hydrolysis 
of synthetic gliadin-derived tripeptide substrates, and by determining the 
degradation of the immunogenic gliadin-derived 33-mer peptide. 
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3. MATERIALS AND METHODS 
3.1 Biological sample collection 
Fecal samples were collected from 3 healthy adults using the Easy Sampler® Stool 
Collection Kit (GP Medical Devices ApS) . All three subjects signed an IRB approved 
informed consent form and were explained how to proceed and to bring the sample 
to the laboratory immediately after collection . BBL CultureSwab ™ (Becton Dickinson 
and Company, Sparks, MD, USA) was used to transport the samples to the 
laboratory. Each cotton swab was contained in a plastic container which was filled 
with 2ml of sterile Phosphate Buffer Saline (PBS). The fecal sample suspensions 
were diluted and cultured as soon as they were received in the laboratory. 
3.2 Preparation of Gluten Agar (GA) 
Gluten Agar (GA) selective plates were made by putting together 23.0 g of gluten 
(Sigma,St. Louis, MO), 5.0 g of sodium chloride (Fisher Scientific, New Jersey, 
USA), 1.0 g of soluble starch (Sigma), 12.0 g of agar No. 2 (Sigma), 0.4 g of sodium 
bicarbonate (J. T. Baker Chemical CO., Phillipsburg, NJ), 1.0 g of glucose (Sigma), 
1.0 g of sodium pyruvate (Sigma), 0.5 g of cysteine HCL monohydrate (Sigma), 1.0 
g of L-arginine (Sigma), 0.25 g of sodium pyrophosphate (Sigma) and 0.5 g of 
sodium succinate (Fisher Scientific) in 1 L deionized water . After mixing all the 
ingredients well, the pH was adjusted to 4.0 and 7.0 using a pH electrode and reader 
(Orion Research Incorporated, USA). Then, the solutions were autoclaved. After 
cooling down to approximately 55°C, 5ml of Vitamin K-Hemin solution (Becton 
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Dickinson and Company) was added to the broth and mixed well. The liquid agar 
was then poured into plastic, sterile petri dishes (Fisher Scientific). Plates were left 
at room temperature for about 24-48 h for solidification to take place. Plates were 
then stored at -20°C. 
3.3 Culturing of the Fecal Samples 
Ten-fold dilution series were made from the fecal sample suspensions in PBS by 
adding 100µ1 to 900µ1 of sterile PBS in a 2 ml Ependorf tube. After vortexing 100µ1 
was removed and added to 900µ1 of sterile PBS. This step was repeated 5 times, 
obtaining 5 different dilutions of the sample. From each dilution (vial) 50µ1 aliquots 
were plated on GA selective plates and incubated at 37°C in aerobic and anaerobic 
conditions (5 plates with the 5 dilutions in aerobic conditions and 5 plates with the 
same 5 dilutions in anaerobic conditions, 20 plates total per sample per pH 
condition). Plates were incubated for 3 days. After incubation , plates were 
macroscopically evaluated and plates where bacteria grew as single colonies were 
chosen for subculturing. From the selected plates, colonies were taken with a sterile 
metallic loop and subcultured to purity on Bruce/la-agar (BA) plates (Hardy 
Diagnostics, Santa Maria, CA, USA). Plates were incubated at 37°C under aerobic 
or anaerobic conditions for 3 days, corresponding to the previous growth condition. If 
needed, colonies were once more subcultured on BA to obtain macroscopically pure 
cultures. Strains, once pure on BA plates, were cultured again on GA plates to 
confirm growth on this selective media. 
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3.3.1 Storage in Glycerol 
Once cultures on BA were pure by macroscopic evaluation cells were harvested 
from the plate using as sterile cotton swab and suspended in a mixture of 
glycerol/Brain Heart Infusion BHI at a (20/80% v/v). Strains were given the 
identification name, FA (Fecal Aerobe) if they were aerobes and FAN (Fecal 
Anaerobe) if they were anaerobes, followed by the pH of the agar on which they 
were cultured (subscript). All vials were labeled indicating the strain's ID, the sample 
it came from and the date and stored at -80°C. 
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Figure 3. Scheme of bacterial culturing from fecal samples. Fecal samples were 
collected from 3 healthy donors and suspended in PBS. 10-fold dilution series were 
made per sample and 50 µI of each dilution was plated on GA plates at pH 4.0 and 
pH 7.0. After 3 days of incubation at 37°C aerobically or anaerobically, cells were 
subcultured to purity on BA and incubated for 3 days also. Once cultured to purity, 
cells were harvested from plate with a sterile cotton swab and stored in a mixture of 
g lycerol/B HI. 
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3.4 Enzyme assays 
In order to test the proteolytic activity of the strains obtained, four different assays 
were performed. 
3.4.1 Gliadin degradation in Gel (Zymography) 
Zymogram gels (6%) were cast following the protocol developed in our laboratory 
(Zamakhchari et al., 2011) using gliadin from wheat (Sigma) as the gel incorporated 
substrate to test enzymatic degradation. Bacteria were suspended in PBS and 
diluted in the same buffer to an 0D 620 of 5.0. A 150µ1 aliquot was centrifuged in an 
Eppendorf Centrifuge (model 5424, Eppendorf, Hamburg, Germany) for 3 minutes at 
15,000rpm. The supernatant was removed and the cells were re-suspended in 25µ1 
of 2 x concentrated zymogram sample buffer containing 0.0625 M Tris/HCI (pH=6.8), 
10% glycerol (v/v), 2% (w/v) SOS and 0.0025% bromophenol blue. The samples 
were applied to the gels and electrophoresis was performed at a constant voltage of 
100 V at 4 °C for approximately 2 hours and 30 minutes until the blue indicator dye 
reached the bottom of the gel. Gels were then immersed in 1 x Novex® zymogram 
renaturing buffer (lnVitrogen, Carlsbad, CA, USA) for 1 h at room temperature, 
changing the buffer after 30 min. For the developing process, gels were washed two 
times of 20 min in 1X Novex® zymogram developing buffer (lnVitrogen) at room 
temperature. After 40 min the gels were incubated at 37°C for 48h in the same 
buffer. The gels were then stained for approximately 16 h in a solution containing 
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0.1 % coomassie blue in 40% (v/v) methanol and 10% (v/v) acetic acid. Destaining 
was achieved using the same solution without the dye in approximately 2h. 
3.4.2 Cleavage of synthetic tripeptide substrates derived from gliadin 
Bacteria were suspended in potassium phosphate buffer (PPB) at pH 4.0 and pH 7.0 
to a final OD620 of 1.2, measured using a spectrophotometer (CARY 50 Scan-UV 
Visible, Varian Inc., Melbourne, Australia) . A 200µ1 aliquot of each bacterial 
suspension was mixed with 2 or 4µ1 of the tripeptide substrates to reach a final 
tripeptide concentration of 200 µM. The substrates used were: Z-YPQ-pNA, Z-LPY-
pNA, Z-QQP-pNA, Z-PPF-pNA, Z-PFP-pNA, Z-QPQ-pNA (21st Century 
Biochemicals, Marlborough , MA). Substrate and bacteria were mixed in a 96-well 
microplate and substrate hydrolysis was evaluated macroscopically, every hour 
observed, as a color change in the solution due to the proteolytic removal of the pNA 
group. In other experiments the color change was monitored spectrophotometrically 
using the GENIUS Plus microplate reader (Tecan Group Ltd., Mannedorf, 
Switzerland) set at 405 nm absorbance. The solution was incubated at 37°C 
between the readings and covered with a plastic to prevent evaporation. 
3.4.3 Degradation of the 33-mer peptide 
Cell suspensions OD620 1.2 were made in sterile PPB at pH 4.0 and 7.0. Chemically 
synthesized 33-mer peptide (21st Century Biochemicals) was prepared and a 25.6 µI 
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aliquot was added to 1.0 ml of the cell suspension to achieve a final 33-mer 
concentration of 250 µg/ml. Samples were incubated in a 37°C water bath. At t= 0, 
2, 5, 8 and 24 h aliquots of 100 µI of the mixture were removed (in duplicate), boiled 
for 10 minutes, and immediately stored in the -80°C freezer. Samples were then 
subjected to RP-HPLC analysis. 
3.4.4 Reversed phase High performance Liquid Chromatography (RP-HPLC) 
To 100µ1 sample aliquots, 900µ1 of buffer A (0.1 % trifluoroacetic acid TFA in 
deionized water) was added. The samples were then filtered using an Acrodisc® 
13mm syringe filter (0.22µm HT Tuffryn® membrane, Pall Corporation, Ann Arbor, 
Ml, USA) and analyzed by RP-HPLC Model 715 using a C18 column (4.6mm ID x 
25cm)(Gilson Scientific Ltd., Bedfordshire, United Kingdom). The 33-mer and its 
fragments were eluted using a gradient of 0-55% buffer B (80% v/v acetonitrile and 
0.1 % v/v TFA) over a 74 min interval. 
3.4.5 Gliadin degradation in SDS-PAGE 
Cells were suspended from BA plates in sterile PPB at pH 2.0, 4.0 and 7.0 to an 
ODs2oof1 .2. Gliadin from wheat (Sigma) was dissolved in 60% ethanol to a final 
concentration of 5 mg/ml. A 50 µI aliquot of the gliadin solution was mixed with 950 
µI of the bacterial cell suspension to reach a final gliadin concentration of 250 µg/ml. 
The solution was vortexed and incubated in a 37°C water bath. At times 0, 2, 5 and 
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8 h, 100µ1 aliquots were removed from each sample and boiled for 10 minutes and 
immediately stored in the -ao0c freezer. Samples were dried on a SpeedVac® Plus 
SC11 QA (Thermo Fisher Scientific Inc.). The pellets were re-suspended in 5µ1 of 4x 
SOS sample buffer containing 0.4mM EOTA, 2% (w/v) sodium dodecyl sulfate 
(SOS), 278 mMTris/HCI (pH=8.5), 292mM sucrose, 0.075% Serva blue G250 (w/v) 
and 0.025% phenol red (w/v) and 15µ1 of de ionized water. Samples were loaded 
onto NuPAGE® 4-12% Bis-Tris gels (lnVitrogen™, Carlsbad, CA, USA). The MES 
running Buffer consisting of 50mM 2-(N-morpholino) ethane sulfonic acid (MES), 
50mMTris base (pH=7.3) and 0.1 % (w/v) SOS. Electrophoresis was carried out at a 
constant voltage of 120 V for approximately 1 h. Gels were then stained in a solution 
containing 0.1 % Coomassie Brilliant Blue in 40% (v/v) methanol and 10% (v/v) 
acetic acid for 24 hours and destained in the same solution without Coomassie blue 
for 2 hours. 
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4. RESULTS 
4.1 Cultivation of strains 
The first aim was to culture microorganisms from human feces. Fecal 
samples were collected from 3 healthy human subjects, diluted in PBS and aliquots 
plated on gluten agar. Bacteria were then subcultured to purity on Bruce/la agar. 
Most plates were incubated for 3 days, some anaerobic strains needed more time to 
grow. An identification number was given to each strain after it was considered pure 
by macroscopic evaluation on the Bruce/la agar plate. Using this approach a total of 
278 strains were obtained from fecal samples from the 3 healthy subjects. 
Some anaerobically cultured strains formed a "halo" on the GA plate, 
characterized by a clear zone in the agar around the colony. This suggested 
degradation of the substrate in the gluten containing agar. 
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Table 1.Number of Strains collected from Fecal Samples of 3 human donors * 
Fecal Sample Aerobically grown Anaerobically grown Total strains # 
Source strains# strains# 
Donor1 53 85 138 
Donor2 30 31 61 
Donor3 44 35 79 
127 151 278 
*Fecal samples were suspended in sterile PBS and diluted aliquots were plated on selective 
GA plates and cultured aerobically or anaerobically at 37°C for 3 days. Successfully grown 
organisms were then subcultured to purity on BA plates and stored in glycerol/SHI (20/80 
v/v) . 
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4.2 Gliadin Zymography 
The first step after obtaining the cells growing on GA was to determine which would 
be able to degrade gliadins. Gliadins contain most of the immunogenic epitopes in 
gluten. Gliadin zymography was used to identify cell-associated enzymatic activities 
directed at the incorporated gliadin substrate. All 278 strains obtained from the fecal 
samples were screened for gliadin degradation by this method. All strains were 
cultured on BA plates for 3 days and suspended in PBS. Aliquots of 150 µI of cells 
(OD620 of 5.0) from each strain were loaded onto the gel. Groups of thirty five strains 
were tested on each day in four zymogram gels. A molecular weight standard was 
included in all the gels and the strain Rothia muci/aginosa (RM) served as the 
positive control in one of the gels ran per day. After electrophoresis, renaturing and 
developing at pH 7.0, and finally staining and distaining of the gels, clear white 
bands in the blue background were observed for some of the tested strains. This 
means that enzymes produced by those strains were capable of degrading the 
gliadin proteins in the gel. There were two trends observed in terms of the apparent 
molecular weight of the enzymes: high molecular weight bands which appeared 
between 150-250kD or medium size molecular weight bands which were observed 
between 50-75kD. Of the 278 strains screened, the anaerobes ( 151) were all 
inactive, and of the aerobes (127) a total of 43 strains showed activity. The gels 
containing the active strains are shown in Figures 4 and 5. Of these, 24 showed the 
high molecular band pattern and 19 showed the medium size molecular weight 
pattern. All active strains were aerobes and 93% of them were isolated from donor ·1·, 
7% from donor 3 and no active strains were isolated from donor 2. Of the 43 active 
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strains, two (FA-1 0pH4 and FA-13pH4) were selected to be evaluated in a gliadin 
zymography assay changing two of the variables: pH of the development buffer and 
number of cells loaded into the gel. Both strains were suspended in PBS. Aliquots of 
150, 50 and 15 µI of cells (0D 620 of 5.0) were loaded onto the gel. Three gels were 
identically loaded and developed at pH 2.0, 4.0 and 7.0. The results showed that the 
two strains were active at all three pH conditions, but the activity was most 
prominent at pH 7.0. As expected, activities decreased with a decrease in cell 
numbers loaded (Figure 6). 
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Table 2. Number of active strains in the gliadin zymogram assay* 
Fecal Sample Aerobically grown Anaerobically grown Total strains# 
Source strains# strains# 
Donor1 40 0 40 . • 
Donor2 0 0 0 
Donor3 3 0 3 
43 0 43 
*All 278 strains were suspended in PBS and diluted in the same buffer to an OD620 of 5.0. 
A 150µ1 aliquot of each strain was subjected to gliadin zymography. Strains were considered 
active when showing a white band in the blue background of the gel. 
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Figure 4. Gliadin degradation by fecal microbial strains in zymogram gels. 
Shown are the results of a selection of the gels that included strains with activity. 
Bacteria were suspended in PBS and diluted in the same buffer to an 00 620 of 5.0. 
A 150µ1 aliquot was centrifuged, the supernatant was removed and the cells were re-
suspended and applied in zymogram sample buffer. The acronyms MW refers to 
molecular weight standard in kDa and RM refers to Rothia Muci/aginosa which was 
included as a positive control. Strains demonstrated either no activity (no clear 
bands), enzyme activity in the 50-75kDa region marked with a red asterisk (*) or 
enzyme activity in the 150-250kDa region marked with a re triangle ~ ). 
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Figure 6. Gliadin degradation in zymogram gels developed at pH 2.0, 4.0 and 
7 .0. Two strains (FA-1 0pH4 and FA-13pH4) were evaluated in zymogram gels 
developed at pH 2.0 , 4 .0 and 7.0. Bacteria were suspended in PBS and diluted in 
the same buffer to an OD52o of 5.0 . Aliquots 150µ1, 50µ1 and 15 µI of each strain was 
centrifuged , the supernatant was removed and the cells were re-suspended and 
applied in zymogram sample buffer. The acronym MW refers to molecular weight 
standard in kDa and RM refers to Rothia mucilaginosa. Note that RM was not active 
at pH 2.0 and 4.0 whereas the two fecal strains showed clear enzyme bands at 
these pH values. 
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4.3 Tripeptide Hydrolysis 
The 43 strains that demonstrated activity in the gliadin zymogram assays were then 
subjected to the synthetic tripeptide cleavage assay. This assay checks the 
cleavage specificity of a mixture of enzymes associated with the microorganisms. 
Strains were suspended in PPB at pH 4.0 and 7.0. Three synthetic tripeptides were 
used Z-YPQ-pNA, Z-LPY-pNA, Z-QQP-pNA. Each was mixed, to a final 
concentration of 200 µM, with 200 µI of each strain ( 0D 620 of 1.2) at each pH. The 
mixtures were incubated at 37°C and macroscopically evaluated for a color change 
from clear to yellow signifying substrate hydrolysis. Examined incubation times were 
7, 19, 24, 48 and ~ 96 hours. At each time point of evaluation the color change was 
recorded, considering a strain capable of cleavage at that specific time. Of the 43 
strains tested, 40 cleaved at least one of the substrates. The tripeptide substrate 
cleaved most frequently and within the shortest incubation time (7h) was Z-LPY-
pNA. It was cleaved by 36 of the 40 strains tested. Most of the strains needed 
relatively long incubation times to cleave any of three substrates (about 24h or 
more). The data are summarized in Figure 7. 
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Figure 7. Hydrolysis of gliadin tripeptides at pH 4.0 and 7 .0. The 43 strains were 
suspended in PPB at pH 4.0 and pH 7.0 to a final ODs20 of 1.2. A 200µ1 aliquot of 
each bacterial suspension was mixed with the tripeptide substrates (final 
concentration 200 µM). The substrates used were: Z-YPQ-pNA, Z-LPY-pNA and Z-
QQP-pNA. Substrate and bacteria were mixed and substrate hydrolysis was 
evaluated macroscopically , at t= 7, 19, 24, 48 and ~ 96 h, as a color change in the 
solution due to the proteolytic removal of the pNA group. Plotted are the 40 active 
strains that showed activity in this assay, on the x-axis the time point of examination 
and on the y-axis the number of strains that turned the solution yellow for the first 
time at that particular time point. 
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4.4 Gliadin degradation in solution 
Two strains FA-1 0pH4 and FA-13pH4 with prominent activity in the gliadin 
zymogram assay (see Figure 6) were chosen to assess gliadin degradation in 
solution using SOS-PAGE gels. Strains were diluted in PPB at pH 2.0, 4.0 and 
7.0 ( 0D 620 of 1.2) and gliadin was added for a final concentration of 250 µg/ml. 
Suspensions were incubated in a 37°C water bath and aliquots were removed at 
t= 0, 2, and 5 hours. Two controls were included in the experiment: bacteria only 
and gliadin only, incubated for the same time intervals. Gliadin degradation was 
evidenced from the disappearance of high molecular weight band from the 
gliadin mixture and appearance of smaller peptides with a higher electrophoretic 
mobility. The two strains were able to fully degrade gliadin at pH 7.0 and partially 
degrade it at pH 4.0 and not degrade it at all at pH 2.0 in the examined time 
period of 5 hours (Figure 8). These results contradict those obtained in gliadin 
zymography (Figure 6), where these two strains showed gliadin degradation at 
pH 2.0 and 4.0. 
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Figure 8. Gliadin degradation in solution by strains FA-1 0pH4 and FA-
13pH4,The two strains were suspended in PPB at pH 2.0, 4.0 and 7.0. Each strain 
( 0D 620 of 1.2) was mixed with gliadin to a final gliadin concentration of 250 µg/ml. 
The suspensions were incubated in a 37°C water bath. Aliquots of 100 µI were 
removed from each sample at 0, 2, and 5 h, boiled for 10 minutes and analyzed 
by SOS PAGE gels. MW refers to molecular weight standard. Left panels: strain 
FA-1 0pH4; right panels: strain FA-13pH4. 
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4.5 33-mer degradation 
Based on similarities in colony morphology, the presence of a clear band in the 
zymogram gel and tripeptide cleavage activity patterns, 22 strains out of the 40 
positive strains for the synthetic substrates cleavage were chosen to be tested in the 
33-mer degradation assay. Each strain ( 0D 620 of 1.2) was mixed with the 33-mer 
peptide at a final concentration of 250 µg/ml and kept in a 37°C water bath. After 0, 5 
and 24 h of incubation, 100µ1 aliquots were removed, boiled , mixed with 900 µI of 
RP-HPLC buffer A and analyzed in RP-HPLC. Three patterns of degradation were 
observed when analyzing the HPLC peak eluting patterns and were graphed 
accordingly. The 33-mer degradation fragments eluting prior to the 33-mer are 
indicated with R 1 or R2 in the graphs (Figure 9, 10, 11 ). Figure 9 shows strains with 
intermediate activities to the 33-peptide , where after 24 h the 33-mer peptide is 
degraded but R 1 and R2 fragments remain; Figure 10 represent strains with high 
activities, where at t= 24 h the 33-mer as well as R 1 and R2 fragments ar~ 
completely degraded, and Figure 11 shows the strains with little or negligible activity 
toward the 33-mer peptide. In table 3 the RP-HPLC results are summarized . Strains 
FA-10pH4 and FA-13pH4, that were previously shown to be active in the gliadin 
zymogram developed at low pH conditions (Figure 6), were further analyzed in the 
33-mer degradation assay in PPB buffer at pH 4.0 and 7.0. Aliquots were removed 
at 0, 2, 5 and 8-hour time points . Both strains were unable to degrade the 33-mer 
peptide at pH 4.0. At pH 7.0, both strains partially degraded the 33-mer peptide at 
t=2 h and completely at t=5 h (Figure 12). 
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Figure 9. Assessment of 33-mer degradation by RP-HPLC, proteolytic pattern 
1. Each tested strain was suspended in PPB ( 0D 620 of 1.2). and mixed with the 33-
mer peptide to a final concentration of 250 µg/ml. The mixture was incubated -~.t 
37°C and 100 µI aliquots were taken at 0, 5 and 24h, boiled, mixed with 900 µI of 
buffer A and analyzed by RP-HPLC. In the graphs, R1 and R2 represent the regions 
containing the fragments resulting from the 33-mer degradation. Pattern 1 is 
characterized by: all 33-mer is degraded at t= 5h; peaks in regions R1 and R2 
eluting just prior the 33-mer; peaks in R 1 and R2 are still present at t= 24. 
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pattern 2. See legend of Figure 9 for details in the procedure. Pattern 2 is 
characterized by: all 33-mer degraded at t= 5h; presence of fragment in R1 eluting 
just before the 33-mer at t = 5 h; complete degradation at t= 24h. 
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degradation of the 33-mer at t= 24 h. 
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Table 3. Summary of the 33-mer degradation patterns observed by RP-HPLC 
analysis .* 
Pattern 33-mer R1 R2 
Time (hr) 0 5 24 0 5 24 0 5 
1 + +/- - - + + - +/-
2 + - - - + - - + 
3 + + + - - + - -
24 
+ 
-
-
*Three degradation patterns could be discerned after analysis of the RP-HPLC 
chromatograms of the 33-mer degradation assays. 33-mer: intact peptide ; R 1: 
region 1, fragments eluting right before the 33-mer peak ; R2: region 2, fragments 
eluting before those in R 1; 0, 5, 24 : time points in h; +: presence ; -: absence of 
peptides in that particular region of the chromatogram . 
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Figure 12. Effects of pH and time (0, 2, 5, 8 h) on 33-mer degradation. Two 
strains (FA-1 0pH4 and FA-13pH4) were suspended in PPB at pH 4.0 and pH 7.0 
( ODs20 of 1.2) and mixed with the 33-mer peptide to a final concentration of 250 
µg/ml and incubated in a 37°C water bath. Aliquots of 100 µI were removed at 0, 2, 5 
and 8 h time points , mixed with 900 µI of buffer A and analyzed by RP-HPLC. No 
activity was observed at pH 4.0. At pH 7 .0 both strains degraded the immunogenic 
33-mer peptide at t= 2 h the peptide is partially degraded , at t= 5h the original 
peptide was abolished and fragments eluting in R1 remained. 
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5. DISCUSSION 
Celiac disease is a common autoimmune and inflammatory disorder of the small 
intestine triggered by the storage proteins present in wheat grains (gliadins and 
glutenins) and other similar grains and manifests in genetically predisposed 
individuals . Different from other autoimmune disorders the treatment is based on 
prevention following a gluten-free diet which is the only effective therapy. For CD 
patients, it is hard to maintain a GFD, since gluten-containing grains are widely used 
in the food industry. Efforts are being made to develop new treatments for this 
condition. 
It has been suggested that prolyl endopeptidases (PEP), enzymes which 
hydrolyze the peptide bond at the carboxyl side of praline residues, can be used as 
a potential co-adjuvant in the proteolysis of harmful gluten peptides, as an oral 
enzyme therapy for CD. There are several reasons why oral enzyme therapy is an 
attractive treatment option for CD, first it targets the exogenous causative agent 
(gluten), second the properties given to the dough by gluten will not be affected and 
finally, it is possible to combine several enzymes that complement each other in the 
degradation of gluten (Bethune et al., 2012). PEP are widely distributed in bacteria, 
fungi, animals and plants (Shan et al. 2004). PEP's from Sphyngomonas capsu/ate 
and Flavobacterium meningosepticum are actively being studied, but they have 
demonstrated to be rapidly proteolyzed by gastric pepsin (Stepniak et al., 2006; 
Shan et al., 2004) and to be inactivated by trypsin and chymotrypsin in the presence 
of intestinal bile salts (Gass et al., 2007). Hordeum vulgare endoprotease (EP-B2) is 
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now being investigated due to its known capability to degrade hordeins which are 
similar to wheat gliadins (Jacobsen and Varner, 1967; Mikkonen et al., 1996). It has 
been demonstrated that EP-B2-mediated cleavage of gluten prevents TG2-mediated 
deamidation at these sites. It has also been demonstrated to be stable in the 
presence of pepsin and to detoxify gluten in vitro and in vivo (Bethune et al., 2006, 
2008; Gass et al., 2006; Siegel et al., 2006) Aspergillus niger (AN) PEP has shown 
to be stable at the different pH conditions present throughout the GI tract (Stepniak 
et al., 2006). PEP's and EP-B2, while being effective, have in common that they are 
not naturally associated with the human body. 
In 2010 Helmerhorst and coworkers, studying the glutamine- and praline-rich 
proteins in saliva observed the rapid degradation of these proteins in the oral cavity 
by oral microbe-associated proteases . They found that these bacteria could also 
cleave dietary gluten, which, like salivary praline-rich proteins, are enriched in the 
XPQ motif. This finding was significant since these gluten-degrading bacteria are 
natural constituents of the human microbiome. The discovery of natural, harmless 
oral bacteria producing gluten-degrading enzymes offers promising new 
opportunities for the development of a novel oral enzyme therapy for celiac disease. 
The purpose of the present study was to isolate gluten-degrading bacteria 
from human feces, a rich source of microbes from the human body. The study was 
undertaken to identify and isolate gluten-degrading microorganism that could 
possibly be explored in the treatment of celiac disease, for instance in the form of a 
probiotic agent, or as an isolated enzyme. A prerequisite of such microbes is not 
only that they are able to cleave gluten effectively, but also that they are active at pH 
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conditions found along the gastrointestinal canal from the oral cavity to the 
duodenum, which range between pH 2.0-7.0. Using a gluten-selective plating 
approach at pH 4.0 and 7.0, 278 strains were obtained from the fecal samples of 
three healthy donors. It was observed that there were noticeable differences in the 
numbers and types of strains obtained from each sample, which suggests that every 
individual has his or her own intestinal microbial flora and consequently, different 
genetic contributions from the colonizing microbes. 
Of the initial 278 strains, 43 showed evidence for gliadin degradation on the 
gliadin zymogram gels. The fact that only 43 of the 278 strains were active in this 
assay emphasizes that growth on GA is only a first step towards the isolation of 
bacteria with activities of interest. Noticeably, the zymogram gels were developed at 
pH 7.0, and therefore bacterial enzymes with optimal activities outside this pH could 
possibly have been missed. Two strains (FA-1 0pH4 and FA-13pH4) were evaluated in 
zymogram gels developed at 3 different pH values: 2,0, 4.0 and 7.0. The rationale 
for conducting assays with these strains at low pH was that both strains had been 
obtained on GA agar at pH 4.0, and therefore might produce enzymes active at 
acidic pH. Secondly , it is of high interest to identify microorganisms that can cleave 
gluten at acidic pH given that the stomach is acidic and ideally gluten are optimally 
digested before they reach the duodenum . The zymogram results for the FA-10pH4 
and FA-13pH4 strains showed that they were active at all three pH values. The result 
was not an artifact since pH of the developing buffer was verified after the 48 h 
incubation time period, and the control strain, Rothia mucilaginosa, which is known 
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to exhibit optimal activities at neutral to basic pH, was inactive in the gels developed 
at pH 4.0 and 2.0. 
The 43 strains displaying activity in the zymogram gels were also evaluated 
with three synthetic tripeptide enzyme substrates, Z-YPQ-pNA, Z-LPY-pNA and Z-
QQP-pNA. The substrates were used to detect post-glutamine, post-tyrosine and 
post-proline cleavage specificities, respectively. Our previous investigations on oral 
gluten-degrading microbes demonstrated that the Z-YPQ-pNA substrate was the 
most frequently and most rapidly cleaved substrate, and hydrolysis of 200 µM 
substrate was completed within a 1 h time frame at a bacterial suspension density of 
OD620 1.2 (Zamakchari et al., 2011). No such rapid substrate hydrolysis was 
observed for any of the 43 fecal strains at the same cell density since hydrolysis was 
first observed after 7 h of incubation. Another distinction from the oral microbe 
studies was that Z-LPY-pNA, and not Z-YPQ-pNA, was the most frequently cleaved 
substrate (by 36 out of 40 strains). LPY is a substrate of high interest, given that it 
occurs repeatedly in the immunogenic 33-mer sequence. In addition, the LPY 
cleavage specificity has not been reported for the enzymes that are currently being 
pursued for the treatment of CD (EP-82 and prolylendopeptideases). In accordance 
with the zymogram results, the optimal pH for tripeptide substrate hydrolysis was pH 
7.0. Virtually no activity was noted towards the QQP substrate. The latter finding 
suggests little to no prolylendopeptidase-producing bacteria to be present in the pool 
of GA-isolated fecal microbes from the three healthy donors. 
FA-10pH4 and FA-13pH4 were further tested for degradation of gliadin in 
solution. The results confirmed activity of these strains towards gliadin under acidic 
so 
conditions (pH 4.0). However, it appeared to be a discrepancy in activities at pH 2.0, 
where the strains were active towards gliadin in gel but not towards gliadin in 
solution. This discrepancy might be explained by the differences in incubation times; 
the zymogram gel is developed for 48 h, whereas the maximal exposure time to 
gliadin in solution was 5 h. In addition, the conformation of gliadin in gel might differ 
from the folding of the gliadins in solution, rendering gliadin domains accessible for 
the enzymes in gel, but not in solution. In conclusion, we have isolated human body-
associated microbes which can degrade gliadins effectively at acidic pH. They also 
cleave the 33-mer, at more neutral pH values. The novel strains may prove to be 
highly valuable new sources of enzymes that might help in combating celiac disease 
and gluten sensitivity. 
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